M8807E Medical-Advisors Bios.Indd
Total Page：16
File Type：pdf, Size：1020Kb
Laboratory Staff Claudia Bunting, HT (ASCP), QIHC (ASCP) Senior Director, Laboratory Operations Claudia Bunting oversees the administrative aspects of the histology, imaging, immunohistochemistry, fl ow cytometry and molecular departments of Clarient. She brings over 30 years of experience in anatomical pathology, with approximately 17 years served in commercial laboratories. She served as Supervisor and then Manager of the Anatomical Department at Ameripath for 14 years and was responsible for developing a fast growing IHC department. In addition, she was the Anatomical Pathology Director at US Labs where she successfully expanded a highly technical IHC laboratory and fl ow cytometry laboratory. She received her histology training at Hurley Hospital in Flint, Michigan. Medical/Advisors/Lab Staff Medical Staff Kenneth J. Bloom, M.D., F.C.A.P. Chief Medical Offi cer Alan Wells Kenneth J. Bloom, MD has been Medical Director since August 2004 and Chief Medical Offi cer since 2005. Dr. Bloom came to Clarient Senior Director, Operations from Irvine, CA-based US Labs, where he served as Senior Medical Director since 2002. Prior to that, Dr. Bloom spent more than two Alan Wells is responsible for logistics, client services, and accessioning at Clarient. He brings to Clarient over 25 years of laboratory operations decades serving in senior academic, consultative and clinical roles with leading hospitals and healthcare enterprises principally in the and management experience. Previously, he was Director of Operations and Purchasing at Oncogenetics Laboratories from its inception specialization of cancer care. as a start-up, where he was responsible for establishing and building all operational functions in addition to human resources, billing and Dr. Bloom’s academic posts have included over 10 years as Associate Professor of Pathology at Chicago-based Rush Medical College, collections, facilities management and warehousing. IMPATH purchased Oncogenetics, and he continued in his role as Director of Operations as well as one year as a visiting Professor in the Department of Computer Science at DePaul University. Over the past 15 years, Dr. for the Phoenix facility until joining Clarient in 2004. Prior to 1992, Alan held a variety of operations and administrative management roles at Bloom has held more than 10 appointed positions at Chicago-based Rush Presbyterian - St. Luke’s Medical Center, one of the leading Genetrix, MetPath/MetWest, Central Diagnostic Laboratory and Automated Pathology Laboratory. cancer research hospitals in the US. Those positions included Director of Laboratory Operations, Director of Immunohistochemistry, and Director of the Breast Service in the Department of Pathology, Consultant to the Rush Breast Cancer Center, and Director of Information Services for the Rush Cancer Institute. Dr. Bloom has, for more than three decades, been a prolifi c researcher and lecturer in the fi elds of pathology and, specifi cally, cancer related topics. During his tenure at Rush, his published studies validating the benefi ts of ACIS® (Automated Cellular Imaging System) image analysis for HER2 evaluation were instrumental in gaining broad acceptance for the Clarient technology. He has been a member of the College of American Pathologists since 1987 and currently serves as a member of the Immunohistochemistry and Technology Assessment Committees for that organization. In addition to US LABS and the other roles mentioned above, Dr. Bloom has served the industry off and on for the past 20 years in both advisory and operational roles. Those appointments include Board of Directors seats, consulting roles and executive posts including executive level positions at both diagnostics technology and information technology fi rms. Todd S. Barry, M.D., Ph.D. Medical Director Todd S. Barry, M.D., Ph.D., joined Clarient in September 2008 as Medical Director. Dr. Barry brings a plethora of innovative experiences and ideas to the Clarient team in an attempt to further cancer diagnostics in the healthcare community. Previously, Dr. Barry was employed by PhenoPath Laboratories, in Seattle, WA, for six years, where he served as the Director of Molecular and Hematopathology. During his tenure in the northwest, Dr. Barry gained extensive experience in the use of morphologic, immunophenotypic, and molecular tools used in the diagnosis and prognosis of hematologic and non-hematologic malignancies. Dr. Barry’s expertise includes: immunohistochemistry, molecular diagnostic testing, fl ow cytometry, leukemias, lymphomas, cutaneous lymphoid disorders, breast pathology, and prognostic and predictive breast cancer biomarkers. He has lectured on these topics in numerous courses for the USCAP, ASCP, CAP, as well as, state and international pathologic societies. Furthermore, in the past two decades, Dr. Barry has published a myriad of articles related to the aforementioned topics and others. Dr. Barry received his M.D. and Ph.D. in Immunology from Duke University in Durham, NC, under the direct supervision of Dr. Barton Haynes (Hanes Professor of Medicine) in 1995. He then completed his residency training in Anatomic and Clinical Pathology at the University of Washington Medical Center in Seattle, WA in 1999. During his last year of residency, he served as Chief Resident and Acting Hematopathology Fellow in Laboratory Medicine, with Dr. Brent Wood and Dr. Steven Kussick. Following his residency training, Dr. Barry fi nished a one year Surgical Pathology/ Immunohistochemistry Fellowship at the University of Washington Medical Center. Additionally, Dr. Barry completed two more years of Hematopathology Fellowship training under Dr. Elaine Jaffe, Dr. Stefania Pittaluga, and Dr. Mark Raffeld at the National Cancer Institute within the National Institutes of Health in Bethesda, Maryland. Sing-Tsung “Steve” Chen, M.D., Ph.D. Director of Hematopathology Dr. Chen is board certifi ed in the areas of Anatomic and Clinical Pathology as well as Hematology. He contributes over 20 years experience in medical research and numerous publications in the fi eld to his credit. Dr. Chen came to Clarient after having been the Director of Hematopathology and Flow Cytometry at US Labs since December 2002. Most recently, he served as Interim Medical Director at the same institution. He received a medical degree from Taipei Medical College, Taipei, Taiwan and completed his residency training in pathology at Temple University School of Medicine, Philadelphia, Pennsylvania. Dr. Chen received a Ph.D. in Molecular and Cellular Pathology from Temple University before moving to neighboring Thomas Jefferson University, Philadelphia, Pennsylvania, where he served as the Associate Director of the Molecular Diagnostic Division and Assistant Professor of Pathology. He completed a fellowship in Hematopathology at the University of Maryland, Baltimore, MD, where he also served as Assistant Professor in the Pathology Department. In 2000 he served as a fellow in Immunohistochemistry in the National Institutes of Health. Dr. Chen joined Quest Diagnostics at Nichols Institute in 2001 as a staff pathologist. His research interests include normal and abnormal cell proliferation. His expertise is in molecular biology and immunohistochemical applications in hematopathology. © Clarient, Inc. M8807E 10/08 31 Columbia, Aliso Viejo, CA 92656 Phone 888.443.3311 Fax 888.443.3345 clarientinc.com Medical Advisory Board Not all advisors may be licensed in California and are not providing patient services in California Anselm “Ants” Hii, M.D., F.C.A.P. Richard J. Cote, M.D., FRCPath Hematopathologist, Director of Consultative Services Chair, Clarient Scientifi c Advisory Board Dr. Hii is a practicing Pathologist and Board Certifi ed in Anatomic and Clinical Pathology as well as Hematology. He received his Medical Specialty - Immunohistochemistry, Molecular Pathology, Genitourinary, Breast and Tumor Pathology Degree as well as residency training at Loma Linda University. Dr. Hii completed his surgical pathology fellowship at the Los Angeles County - Richard J. Cote, M.D., FRCPath is a board certifi ed Anatomical Pathologist who has served over 20 years in senior academic, consultative, and University of Southern California Medical Center and a fellowship in Hematopathology at Cedars-Sinai Medical Center in Los Angeles. He has director/clinical roles with leading hospitals and healthcare enterprises primarily in the area of cancer care. previously served as Associate Medical Director at US Labs. He received his medical degree from the University of Chicago - Pritzker School of Medicine. He completed his residency at Cornell University Dr. Hii currently is the California Tumor Tissue Registry Co-Director for Web and Multimedia Development. He is a member of the College of Medical College, New York. He served a clinical fellowship in pathology at Memorial Sloan-Kettering Cancer Center, a research fellowship in American Pathologists, American Society for Clinical Pathology, and American Society of Hematology. Human Tumor Immunology at Memorial Sloan-Kettering Cancer Center and a fellowship in Molecular Pathology at New York University School of Medicine. He currently serves as Professor, Department of Pathology, Professor, Department of Urology, Director, Genitourinary Program, Chair, USC Biomedical Nanosciences Initiative, and Director, Laboratory of Immunology and Molecular Pathology at University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center in Los Angeles. Dr. Cote was the founder of IMPATH,